Overview

68Ga-AAZTA-093 PET/CT: First-in-human Study

Status:
RECRUITING
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
68Ga-AAZTA-093 is a novel radiotracer targeting prostate-specific membrane antigen (PSMA). In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-AAZTA-093 PET/CT in patients with prostate cancer.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University